Melperone Ratiopharm

Melperone, the active ingredient in Melperone Ratiopharm, is a butyrophenone‑type typical antipsychotic presented as an oral tablet. It is used to manage schizophrenia and acute psychotic episodes in adult patients, acting on central dopamine pathways to reduce psychotic symptoms.

GNH USA supplies Melperone Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards. The product currently conforms to European Union marketing authorisation requirements and is manufactured under GMP conditions.

Melperone is a typical antipsychotic that modulates dopaminergic activity in schizophrenia and related psychotic disorders.

Schizophrenia: reduces positive symptoms such as hallucinations, delusions, and thought disorder. Acute psychotic episodes: rapidly controls sudden exacerbations of psychosis, improving agitation and confusion. Maintenance therapy in chronic psychosis: helps prevent relapse and maintain symptom stability over the long term. Adjunctive therapy in treatment‑resistant psychosis: may be combined with other antipsychotics when response is inadequate. Off‑label use in severe agitation: can be considered for short‑term control of extreme agitation in psychiatric settings.

Common Side Effects: - Drowsiness - Dry mouth - Constipation - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Seizures - Agranulocytosis

Precautions should be taken to minimise risks and monitor patient safety. - Dose adjustment in hepatic impairment: reduce dose as needed. - Monitor for extrapyramidal symptoms: assess regularly. - Assess cardiovascular status: watch for orthostatic hypotension. - Avoid abrupt discontinuation: taper under medical supervision. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Melperone may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): may increase melperone plasma levels. - CNS depressants (e.g., benzodiazepines): additive sedation risk. - Anticholinergic agents: may mask extrapyramidal symptoms.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): possible altered plasma concentrations. - Antihypertensives: additive hypotensive effect. - Lithium: monitor for increased neurotoxicity.